Clarissa Harvey, PA
Medical · Cuyahoga Falls, OHNPI 1235890278
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,327 of the $7,289 with a category attached, or 86.8%. 35 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 27.5% of the total. Among medical clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 303 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- AstraZeneca$865
- Sanofi$639
- GSK$595
- Boehringer Ingelheim$324
- United Therapeutics Corporation$297
- plus $3K from 29 others
What the payments were for
- Travel & lodging$86212%
- Food & beverage$6,32787%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 26 | $2,006 |
| AstraZeneca | 40 | $865 |
| Sanofi | 31 | $639 |
| GSK | 52 | $595 |
| Boehringer Ingelheim | 18 | $324 |
| United Therapeutics Corporation | 12 | $297 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $296 |
| Harmony Biosciences LLC | 9 | $253 |
| Amgen | 13 | $226 |
| Regeneron Healthcare Solutions, Inc. | 11 | $197 |
| Mallinckrodt Hospital Products Inc. | 5 | $159 |
| Verona Pharma, Inc. | 12 | $149 |
| Genentech USA, Inc. | 5 | $122 |
| Merck | 6 | $116 |
| Mylan Specialty L.p. | 5 | $102 |
| Actelion Pharmaceuticals US, Inc. | 4 | $92 |
| Grifols USA, LLC | 5 | $91 |
| Philips North America LLC | 5 | $89 |
| Insmed, Inc. | 4 | $85 |
| Jazz Pharmaceuticals Inc. | 3 | $84 |
| Baxter Healthcare | 3 | $74 |
| Pfizer | 4 | $74 |
| Inogen, Inc. | 3 | $52 |
| Novartis | 2 | $43 |
| Optinose US, Inc. | 2 | $39 |
| Vifor Pharma, Inc. | 2 | $37 |
| Viatris Specialty LLC | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $19 |
| Electromed, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Biomerieux Inc | 1 | $15 |
| Resmed Corp | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,289 in reported general payments places this provider in the 90th percentile of 547 medical providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 210 | $186,451 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $171,887 |
| Dupixent PenDupilumab | 35 | $143,512 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 106 | $90,585 |
| OfevNintedanib Esylate | 12 | $72,903 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 76 | $47,817 |
| NucalaMepolizumab | 12 | $44,266 |
| Spiriva RespimatTiotropium Bromide | 33 | $33,552 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 35 | $31,145 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $21,147 |
| EliquisApixaban | 32 | $19,083 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $12,524 |
| Arnuity ElliptaFluticasone Furoate | 39 | $12,474 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $9,597 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $9,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $595 | $324,679389 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $324 | $137,60080 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $865 | $98,722130 claims |
| PfizerEliquis | $74 | $19,08332 claims |
| MerckDulera | $116 | $5,06912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 547 medical providers in Ohio.
Other medical in Cuyahoga Falls
- Shannon GhizzoniColumbus$116K
- Susan WhittCanal Winchester$74K
- Christopher FrickLima$46K
- Kodi VealeAkron$43K
- Abbey BlairCleveland$24K
- Joana ZulaConcord Twp$23K
- Chelsea AustenColumbus$21K
- Kristen FairchildToledo$19K
- Kaitlin SchuppGahanna$17K
- Melanie HunglerCincinnati$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.